



S Genetics Chooses XIFIN for Revenue Cycle Management and Commercialization Strategies for New Pediatric Genetic Test

Leading Revenue Cycle Management Company Continues Expansion in MDx Market

San Diego, CA – February 1, 2011 - XIFIN Inc., the leading provider of [revenue cycle management](#) for diagnostic service providers, announced today that JS Genetics, Inc., a diagnostic company with laboratory facilities in New Haven, CT focused on the development of genetic diagnostic tests for the pediatric market, has selected XIFIN to manage its >billing and claims management needs and monitor revenue cycle and financial performance. XIFIN is also providing consulting services to help JS Genetics successfully commercialize XCAT-TS, its proprietary pediatric molecular diagnostic (MDx) X chromosome abnormality test for Turner Syndrome.

Designed around industry best practices, and used by the majority of the nation's largest laboratories, XIFIN's revenue cycle management system and services provide diagnostic service providers with new levels of automation and actionable management information to refine revenue cycle processes, improve cash collections and reduce operational costs. JS Genetics develops proprietary, reasonably priced, diagnostic tests for underserved medical conditions in newborns, children and adolescents. The company markets accurate, convenient and cost effective DNA screening tests for adolescents focused on physical, cognitive and behavioral development disorders.

"XIFIN has a proven track record of helping molecular diagnostic companies successfully manage the unique complexities of our market's billing and accounts receivable management activities," stated Alidad Mireskandari, CEO of JS Genetics. "We especially like the fact that XIFIN focuses exclusively on laboratory billing, and has [expertise in MDx and personalized medicine strategies](#), which gives us confidence in their ability to meet both our billing and commercialization needs."

"It is wonderful to work with a company like JS Genetics who recognizes the importance of addressing reimbursement strategies during the commercialization phase in order to maximize revenue and gain a competitive advantage," stated [Rina Wolf](#), VP of Commercialization Strategies, Consulting and Industry Affairs at XIFIN. "JS Genetics is doing all the right things to ensure the success of its new Turner Syndrome test within the pediatric diagnostics market for personalized medicine."

XIFIN has processed more than 150 million claims for a variety of diagnostic service providers across various healthcare segments including clinical, hospital outreach, anatomic pathology, molecular diagnostics, therapeutic pain management, radiology and more.

About JS Genetics

JS Genetics Inc. develops and markets proprietary, low cost, high value DNA diagnostic tests for underserved medical conditions in newborns, children, and adolescents. This focus grew out of the recognition that most genetic tests require blood samples, have longer turn-around times, and are expensive. The company's principal strategy is to internally develop tests using cheek swabs for sample collection and a PCR-based testing platform to bring to market accurate, convenient and cost effective DNA screening tests.

About XIFIN

XIFIN is a Software-as-a-Service (SaaS) provider of revenue cycle management solutions that help diagnostic service providers improve financial performance and enhance operational efficiency with a compelling return on investment and rapid time-to-value. The company has received continual industry recognition, including being named to the Inc. 5000 fastest growing privately-held companies 2007 through 2010, and ranking among Deloitte's Technology Fast 500.